Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
The cytocompatability of polyhydroxyalkanoates coated with a fusion protein of PHA repressor protein (PhaR) and Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) polypeptide.
- Cui-Ling Dong, Shiyan Li, +4 authors G. Chen
- Materials Science, Medicine
- Biomaterials
- 1 March 2012
Microbial polyhydroxyalkanoates (PHAs) are a family of polyesters with biodegradability, biocompatibility and adjustable mechanical properties that are under intensive development for bioimplant… Expand
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
- Shiyan Li, Yizhen Liu
- Medicine
- Clinical pharmacology : advances and applications
- 2 September 2013
Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical… Expand
Research progress of inducible nitric oxide synthase regulation
Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO), and it also plays an important roles in inflammation, infection and cancer.Gene polymorphism of iNOS is related to some diseases,… Expand
Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
- Fengjie Tang, Shiyan Li, Dai-song Liu, J. Chen, C. Han
- Medicine
- 19 February 2020
Melanoma (MM) is a kind of malignant tumor which originates from melanocytes, and accounts for 3–5% of skin malignant tumors. It has high malignancy and is prone to invasion and metastasis (1),… Expand
Enhanced anticancer activity of core-surface-crosslinked nanoparticles
- P. Xu, E. Kirk, +4 authors Youqing Shen
- Chemistry
- 2004
Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis
- Can Liu, Siqi He, Jian-fei Zhang, Shiyan Li, J. Chen, C. Han
- Chemistry, Medicine
- OncoTargets and therapy
- 29 May 2020
Background Vemurafenib is a selective BRAF inhibitor with significant early effects in melanoma, but resistance will develop with the duration of treatment. Therefore, overcoming vemurafenib… Expand
Urokinase-targeted recombinant bacterial protein toxins — a rationally designed and engineered anticancer agent for cancer therapy
- Yizhen Liu, Shiyan Li
- Biology
- Frontiers of Biology in China
- 5 March 2009
Urokinase-targeted recombinant bacterial protein toxins are a sort of rationally designed and engineered anticancer recombinant fusion proteins representing a novel class of agents for cancer… Expand